Abstract
Patients/Materials and Methods: Fourteen patients were treated with bevacizumab after at least 4-mm tumor growth was demonstrated over 12 months in either intracranial or peripheral nerve schwannoma. The main outcome measures were tumor response and hearing outcomes during the first 6 months of treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Neurological Surgery Part B: Skull Base
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
